Peptide Comparison
Prostamax vs Chonluten
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Prostamax and Chonluten share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Prostamax | Chonluten | |
|---|---|---|
| Class | Khavinson peptide bioregulator | Khavinson short peptide bioregulator |
| Drug class | Other & Emerging | Tissue Repair |
| Mechanism | Tissue-specific gene expression in prostate | Tissue-specific gene expression modulation in respiratory epithelium |
| Route | Oral | Oral / Intranasal |
| Half-life | Short (minutes) | Short (minutes) |
| Dosage (research) | Oral capsule 1-2x daily | Oral capsule 1-2x daily |
| Evidence tier | Russian Research | Russian Research |
| Research depth | 5 indexed | 3 indexed |
| Availability | Research | Research |
| Reported risks | Limited Western data | Limited Western evidence |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Prostamax or Chonluten?
Prostamax and Chonluten share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
What is the difference between Prostamax and Chonluten?
Prostamax is classed as Khavinson peptide bioregulator; Chonluten is classed as Khavinson short peptide bioregulator. Reported mechanism: Prostamax, Tissue-specific gene expression in prostate; Chonluten, Tissue-specific gene expression modulation in respiratory epithelium. Reported half-life: Prostamax, Short (minutes); Chonluten, Short (minutes). Routes in published studies: Prostamax, Oral; Chonluten, Oral / Intranasal.
Which has stronger evidence, Prostamax or Chonluten?
Prostamax and Chonluten sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Prostamax is graded Russian Research, with 2 cited sources on its reference page and 5 indexed studies. Chonluten is graded Russian Research, with 2 cited sources on its reference page and 3 indexed studies.
Which is more accessible, Prostamax or Chonluten?
Neither Prostamax nor Chonluten is an FDA-approved drug. Catalog status: Prostamax, Research; Chonluten, Research.
Are Prostamax and Chonluten ever combined?
Prostamax and Chonluten appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…